Table 1 Baseline characteristics of the study population

	Controls	HTN(T2DM-)	HTN(T2DM +)	P value
	n = 49	n = 85	n = 58
Demographics
Female, n (%)	23(46.9)	39(45.9)	27(46.6)	1.000
Age (year)	56.6 ± 10.1	57.0 ± 12.4	59.5 ± 9.2	0.294
BMI (kg/m²)	22.85 ± 3.01	24.88 ± 2.85*	24.64 ± 3.06*	0.001
BSA (m²)	1.68 ± 0.19	1.74 ± 0.20	1.70 ± 0.15	0.156
Smoking, n (%)	0	28(37.3)	15(31.3)	0.563
Duration of hypertension (year)	0	7.5 ± 8.7	7.7 ± 8.2	0.875
Duration of diabetes (year)	0	0	8.6 ± 5.3
Laboratory data
Fasting blood glucose (mmol/L)	5.65 ± 1.61	5.31 ± 0.84	7.94 ± 2.94*§	< 0.001
Plasma triglycerides (mmol/L)	1.51 ± 0.85	1.89 ± 1.68	1.77 ± 1.57	0.471
Total cholesterol (mmol/L)	4.56 ± 0.89	4.43 ± 1.02	4.15 ± 0.82	0.098
HDL (mmol/L)	1.29 ± 0.32	1.31 ± 0.47	1.20 ± 0.34	0.259
LDL (mmol/L)	2.72 ± 0.78	2.49 ± 0.84	2.38 ± 0.73	0.153
eGFR (mL/min/1.73m²)	92.17 ± 17.89	89.890 ± 19.57	87.16 ± 20.80	0.487
Hemodynamic variables
Heart rate(beats/min)	72.7 ± 11.8	73.8 ± 13.0	73.4 ± 11.1	0.877
SBP (mmHg)	119.7 ± 14.6	139.0 ± 20.8*	135.0 ± 17.1*	< 0.001
DBP (mmHg)	73.7 ± 8.7	86.3 ± 13.9*	81.9 ± 9.8*	< 0.001
Antihypertensive medication
ACEI/ARB, n (%)	0	37(43.5)	27 (46.6)	0.735
Bta-blocker, n (%)	0	30 (35.3)	19 (32.8)	0.858
Calcium channel blocker, n (%)	0	51 (60.7)	30 (51.7)	0.306
Diuretics, n (%)	0	13 (15.3)	10 (17.2)	0.818
Antidiabetic medication
Oral, n (%)	0	0	44 (75.9)
Insulin, n (%)	0	0	16 (27.6)

Values are mean ± standard deviation, numbers in the brackets are percentage
eGFR estimated glomerular filtration rate, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker
^*p < 0.05 vs. controls
^§P < 0.05 vs. controls and HTN (T2DM-) group

ISSN: 1475-2840